Benzinga | Mar 26, 2021 12:01PM EDT

JonesTrading Downgrades Celyad Oncology to Hold

JonesTrading analyst Soumit Roy downgrades Celyad Oncology (NASDAQ:CYAD) from Buy to Hold.